$16M will double staff for cancer drug co.

Credit: Courtesy photo

A new $16 million funding round will not only help Blend Therapeutics double its employee headcount, it will allow the firm to advance two of its cancer-cell killing drugs, according to the Watertown-based company’s new chief executive officer.

“We have the chance to go out there and be in the most utilized categories in cancer medicine,” said Blend CEO Mark Iwicki, 46. “That’s a big opportunity.”

The article you requested has been archived

All coverage within bostonherald.com from the last 14 days remains free of charge. Articles do not always include original photos, charts or graphics.